|
1
|
Lazaridis KN and Gores GJ:
Cholangiocarcinoma. Gastroenterology. 128:1655–1667. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Patel T: Worldwide trends in mortality
from biliary tract malignancies. BMC Cancer. 2:102002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gores GJ: Cholangiocarcinoma: Current
concepts and insights. Hepatology. 37:961–969. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lyons JF, Wilhelm S, Hibner B and Bollag
G: Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer.
8:219–225. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wilhelm SM, Carter C, Tang L, Wilkie D,
McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al:
BAY 43-9006 exhibits broad spectrum oral antitumor activity and
targets the RAF/MEK/ERK pathway and receptor tyrosine kinases
involved in tumor progression and angiogenesis. Cancer Res.
64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al SHARP Investigators Study Group, : Sorafenib in advanced
hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bengala C, Bertolini F, Malavasi N, Boni
C, Aitini E, Dealis C, Zironi S, Depenni R, Fontana A, Del Giovane
C, et al: Sorafenib in patients with advanced biliary tract
carcinoma: A phase II trial. Br J Cancer. 102:68–72. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
El-Khoueiry AB, Rankin C, Siegel AB, Iqbal
S, Gong IY, Micetich KC, Kayaleh OR, Lenz HJ and Blanke CD: S0941:
A phase 2 SWOG study of sorafenib and erlotinib in patients with
advanced gallbladder carcinoma or cholangiocarcinoma. Br J Cancer.
110:882–887. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sugiyama H, Onuki K, Ishige K, Baba N,
Ueda T, Matsuda S, Takeuchi K, Onodera M, Nakanuma Y, Yamato M, et
al: Potent in vitro and in vivo antitumor activity of sorafenib
against human intrahepatic cholangiocarcinoma cells. J
Gastroenterol. 46:779–789. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Blechacz BR, Smoot RL, Bronk SF, Werneburg
NW, Sirica AE and Gores GJ: Sorafenib inhibits signal transducer
and activator of transcription-3 signaling in cholangiocarcinoma
cells by activating the phosphatase shatterproof 2. Hepatology.
50:1861–1870. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Masuda M, Chen WY, Miyanaga A, Nakamura Y,
Kawasaki K, Sakuma T, Ono M, Chen CL, Honda K and Yamada T:
Alternative mammalian target of rapamycin (mTOR) signal activation
in sorafenib-resistant hepatocellular carcinoma cells revealed by
array-based pathway profiling. Mol Cell Proteomics. 13:1429–1438.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhai B, Hu F, Jiang X, Xu J, Zhao D, Liu
B, Pan S, Dong X, Tan G, Wei Z, et al: Inhibition of Akt reverses
the acquired resistance to sorafenib by switching protective
autophagy to autophagic cell death in hepatocellular carcinoma. Mol
Cancer Ther. 13:1589–1598. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chiarini F, Evangelisti C, McCubrey JA and
Martelli AM: Current treatment strategies for inhibiting mTOR in
cancer. Trends Pharmacol Sci. 36:124–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Laplante M and Sabatini DM: mTOR signaling
at a glance. J Cell Sci. 122:3589–3594. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dunlop EA and Tee AR: mTOR and autophagy:
A dynamic relationship governed by nutrients and energy. Semin Cell
Dev Biol. 36:121–129. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Laplante M and Sabatini DM: mTOR signaling
in growth control and disease. Cell. 149:274–293. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Morrison Joly M, Hicks DJ, Jones B,
Sanchez V, Estrada MV, Young C, Williams M, Rexer BN, Sarbassov D,
Muller WJ, et al: Rictor/mTORC2 drives progression and therapeutic
resistance of HER2-amplified breast cancers. Cancer Res.
76:4752–4764. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Horiuchi A, Nikaido T, Taniguchi S and
Fujii S: Possible role of calponin h1 as a tumor suppressor in
human uterine leiomyosarcoma. J Natl Cancer Inst. 91:790–796. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Soares HP, Ming M, Mellon M, Young SH, Han
L, Sinnet-Smith J and Rozengurt E: Dual PI3K/mTOR Inhibitors Induce
Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic
Cancer Cells through Suppression of mTORC2. Mol Cancer Ther.
14:1014–1023. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Copp J, Manning G and Hunter T:
TORC-specific phosphorylation of mammalian target of rapamycin
(mTOR): phospho-Ser2481 is a marker for intact mTOR signaling
complex 2. Cancer Res. 69:1821–1827. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Guan DX, Shi J, Zhang Y, Zhao JS, Long LY,
Chen TW, Zhang EB, Feng YY, Bao WD, Deng YZ, et al: Sorafenib
enriches epithelial cell adhesion molecule-positive tumor
initiating cells and exacerbates a subtype of hepatocellular
carcinoma through TSC2-AKT cascade. Hepatology. 62:1791–1803. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wilson JM, Kunnimalaiyaan S,
Kunnimalaiyaan M and Gamblin TC: Inhibition of the AKT pathway in
cholangiocarcinoma by MK2206 reduces cellular viability via
induction of apoptosis. Cancer Cell Int. 15:132015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ewald F, Grabinski N, Grottke A, Windhorst
S, Nörz D, Carstensen L, Staufer K, Hofmann BT, Diehl F, David K,
et al: Combined targeting of AKT and mTOR using MK-2206 and RAD001
is synergistic in the treatment of cholangiocarcinoma. Int J
Cancer. 133:2065–2076. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Salazar M, Lorente M, García-Taboada E,
Pérez Gómez E, Dávila D, Zúñiga-García P, María Flores J, Rodríguez
A, Hegedus Z, Mosén-Ansorena D, et al: Loss of Tribbles
pseudokinase-3 promotes Akt-driven tumorigenesis via FOXO
inactivation. Cell Death Differ. 22:131–144. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang J, Liu S, Yin Y, Li M, Wang B, Yang L
and Jiang Y: FOXO3-mediated up-regulation of Bim contributes to
rhein-induced cancer cell apoptosis. Apoptosis. 20:399–409. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shimizu S, Takehara T, Hikita H, Kodama T,
Tsunematsu H, Miyagi T, Hosui A, Ishida H, Tatsumi T, Kanto T, et
al: Inhibition of autophagy potentiates the antitumor effect of the
multikinase inhibitor sorafenib in hepatocellular carcinoma. Int J
Cancer. 131:548–557. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huynh H, Ngo VC, Koong HN, Poon D, Choo
SP, Thng CH, Chow P, Ong HS, Chung A and Soo KC: Sorafenib and
rapamycin induce growth suppression in mouse models of
hepatocellular carcinoma. J Cell Mol Med. 13(8B): 1–2683. 2009.
View Article : Google Scholar
|
|
28
|
Jacinto E, Loewith R, Schmidt A, Lin S,
Rüegg MA, Hall A and Hall MN: Mammalian TOR complex 2 controls the
actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol.
6:1122–1128. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hisamatsu T, Mabuchi S, Matsumoto Y,
Kawano M, Sasano T, Takahashi R, Sawada K, Ito K, Kurachi H,
Schilder RJ, et al: Potential role of mTORC2 as a therapeutic
target in clear cell carcinoma of the ovary. Mol Cancer Ther.
12:1367–1377. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pignochino Y, Del l'Aglio C, Basiricò M,
Capozzi F, Soster M, Marchiò S, Bruno S, Gammaitoni L, Sangiolo D,
Torchiaro E, et al: The combination of sorafenib and everolimus
abrogates mTORC1 and mTORC2 upregulation in osteosarcoma
preclinical models. Clin Cancer Res. 19:2117–2131. 2013. View Article : Google Scholar : PubMed/NCBI
|
